Skip to Content

Ranexa Approval History

FDA Approved: Yes (First approved January 27, 2006)
Brand name: Ranexa
Generic name: ranolazine
Dosage form: Extended-Release Tablets
Company: CV Therapeutics, Inc.
Treatment for: Angina

Ranexa (ranolazine) is an antianginal and anti-ischemic agent indicated for the treatment of chronic angina.

Development History and FDA Approval Process for Ranexa

DateArticle
Nov  6, 2008Approval FDA Approves Ranexa for First Line Anti Anginal Use
Dec 19, 2007Approval FDA Approves New Mechanism of Action Labeling for Ranexa
Aug 14, 2007Approval CV Therapeutics Launches 1000 mg Ranexa Tablet
Jan 27, 2006Approval Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina
Jul 27, 2005CV Therapeutics Submits Amendment to Ranexa (ranolazine)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide